Discovery of the magnetic field of the B1/B2V star \sigma Lupi

In our search for new magnetic massive stars we use the strongest indirect indicator of a magnetic field in B stars, which is periodic variability of UV stellar wind lines occurring in a velocity range symmetric around zero. Our aim is to obtain follow-up spectropolarimetry to search for a magnetic field in magnetic candidate stars. We quantify UV wind line variability, and analyse its time behaviour. The B1/B2V star sigma Lup emerged as a new magnetic candidate star. AAT spectropolarimetric measurements with SEMPOL were obtained. The stellar wind line variations of sigma Lup are similar to what is known in magnetic B stars, but no periodicity could be determined. We detected a longitudinal magnetic field with varying strength and amplitude of about 100 G with error bars of typically 20 G, which supports an oblique magnetic-rotator configuration. The equivalent width variations of the UV lines, the magnetic and the optical line variations are consistent with the well-known photometric period of 3.02 days, which we identify with the rotation period of the star. Additional observations with ESPaDOnS at CFHT strongly confirmed this discovery, and allowed to determine a precise magnetic period. Further analysis revealed that $\sigma$ Lupi is a helium-strong star, with an enhanced nitrogen abundance and an underabundance of carbon, and has a spotted surface. We conclude that sigma Lup is a magnetic oblique rotator, and is a He-strong star. It is the 4th B star for which a magnetic field is discovered from studying only its wind variability. Like in the other magnetic B stars the wind emission originates in the magnetic equator, with maximum emission occurring when a magnetic pole points towards the Earth. The 3.02 d magnetic rotation period is consistent with the photometric period, with maximum light corresponding to maximum magnetic field. A full paper will be submitted to A&A.Comment: 4 pages, 5 figures, to appear in proceedings with AIP. Stellar polarimetry: From birth to death, Eds. Jennifer Hoffman, Barb Whitney, and Jon Bjorkma

An algebraic proof of Bogomolov-Tian-Todorov theorem

We give a completely algebraic proof of the Bogomolov-Tian-Todorov theorem. More precisely, we shall prove that if X is a smooth projective variety with trivial canonical bundle defined over an algebraically closed field of characteristic 0, then the L-infinity algebra governing infinitesimal deformations of X is quasi-isomorphic to an abelian differential graded Lie algebra.Comment: 20 pages, amspro

Proof of the Hyperplane Zeros Conjecture of Lagarias and Wang

We prove that a real analytic subset of a torus group that is contained in its image under an expanding endomorphism is a finite union of translates of closed subgroups. This confirms the hyperplane zeros conjecture of Lagarias and Wang for real analytic varieties. Our proof uses real analytic geometry, topological dynamics and Fourier analysis.Comment: 25 page

Transfer Matrices and Partition-Function Zeros for Antiferromagnetic Potts Models. V. Further Results for the Square-Lattice Chromatic Polynomial

We derive some new structural results for the transfer matrix of square-lattice Potts models with free and cylindrical boundary conditions. In particular, we obtain explicit closed-form expressions for the dominant (at large |q|) diagonal entry in the transfer matrix, for arbitrary widths m, as the solution of a special one-dimensional polymer model. We also obtain the large-q expansion of the bulk and surface (resp. corner) free energies for the zero-temperature antiferromagnet (= chromatic polynomial) through order q^{-47} (resp. q^{-46}). Finally, we compute chromatic roots for strips of widths 9 <= m <= 12 with free boundary conditions and locate roughly the limiting curves.Comment: 111 pages (LaTeX2e). Includes tex file, three sty files, and 19 Postscript figures. Also included are Mathematica files data_CYL.m and data_FREE.m. Many changes from version 1: new material on series expansions and their analysis, and several proofs of previously conjectured results. Final version to be published in J. Stat. Phy

Transfer matrices and partition-function zeros for antiferromagnetic Potts models. VI. Square lattice with special boundary conditions

We study, using transfer-matrix methods, the partition-function zeros of the square-lattice q-state Potts antiferromagnet at zero temperature (= square-lattice chromatic polynomial) for the special boundary conditions that are obtained from an m x n grid with free boundary conditions by adjoining one new vertex adjacent to all the sites in the leftmost column and a second new vertex adjacent to all the sites in the rightmost column. We provide numerical evidence that the partition-function zeros are becoming dense everywhere in the complex q-plane outside the limiting curve B_\infty(sq) for this model with ordinary (e.g. free or cylindrical) boundary conditions. Despite this, the infinite-volume free energy is perfectly analytic in this region.Comment: 114 pages (LaTeX2e). Includes tex file, three sty files, and 23 Postscript figures. Also included are Mathematica files data_Eq.m, data_Neq.m,and data_Diff.m. Many changes from version 1, including several proofs of previously conjectured results. Final version to be published in J. Stat. Phy

Spanning forests and the q-state Potts model in the limit q \to 0

We study the q-state Potts model with nearest-neighbor coupling v=e^{\beta J}-1 in the limit q,v \to 0 with the ratio w = v/q held fixed. Combinatorially, this limit gives rise to the generating polynomial of spanning forests; physically, it provides information about the Potts-model phase diagram in the neighborhood of (q,v) = (0,0). We have studied this model on the square and triangular lattices, using a transfer-matrix approach at both real and complex values of w. For both lattices, we have computed the symbolic transfer matrices for cylindrical strips of widths 2 \le L \le 10, as well as the limiting curves of partition-function zeros in the complex w-plane. For real w, we find two distinct phases separated by a transition point w=w_0, where w_0 = -1/4 (resp. w_0 = -0.1753 \pm 0.0002) for the square (resp. triangular) lattice. For w > w_0 we find a non-critical disordered phase, while for w < w_0 our results are compatible with a massless Berker-Kadanoff phase with conformal charge c = -2 and leading thermal scaling dimension x_{T,1} = 2 (marginal operator). At w = w_0 we find a "first-order critical point": the first derivative of the free energy is discontinuous at w_0, while the correlation length diverges as w \downarrow w_0 (and is infinite at w = w_0). The critical behavior at w = w_0 seems to be the same for both lattices and it differs from that of the Berker-Kadanoff phase: our results suggest that the conformal charge is c = -1, the leading thermal scaling dimension is x_{T,1} = 0, and the critical exponents are \nu = 1/d = 1/2 and \alpha = 1.Comment: 131 pages (LaTeX2e). Includes tex file, three sty files, and 65 Postscript figures. Also included are Mathematica files forests_sq_2-9P.m and forests_tri_2-9P.m. Final journal versio

A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial

Background Cough can be a debilitating symptom of idiopathic pulmonary fibrosis (IPF) and is difficult to treat. PA101 is a novel formulation of sodium cromoglicate delivered via a high-efficiency eFlow nebuliser that achieves significantly higher drug deposition in the lung compared with the existing formulations. We aimed to test the efficacy and safety of inhaled PA101 in patients with IPF and chronic cough and, to explore the antitussive mechanism of PA101, patients with chronic idiopathic cough (CIC) were also studied. Methods This pilot, proof-of-concept study consisted of a randomised, double-blind, placebo-controlled trial in patients with IPF and chronic cough and a parallel study of similar design in patients with CIC. Participants with IPF and chronic cough recruited from seven centres in the UK and the Netherlands were randomly assigned (1:1, using a computer-generated randomisation schedule) by site staff to receive PA101 (40 mg) or matching placebo three times a day via oral inhalation for 2 weeks, followed by a 2 week washout, and then crossed over to the other arm. Study participants, investigators, study staff, and the sponsor were masked to group assignment until all participants had completed the study. The primary efficacy endpoint was change from baseline in objective daytime cough frequency (from 24 h acoustic recording, Leicester Cough Monitor). The primary efficacy analysis included all participants who received at least one dose of study drug and had at least one post-baseline efficacy measurement. Safety analysis included all those who took at least one dose of study drug. In the second cohort, participants with CIC were randomly assigned in a study across four centres with similar design and endpoints. The study was registered with ClinicalTrials.gov (NCT02412020) and the EU Clinical Trials Register (EudraCT Number 2014-004025-40) and both cohorts are closed to new participants. Findings Between Feb 13, 2015, and Feb 2, 2016, 24 participants with IPF were randomly assigned to treatment groups. 28 participants with CIC were enrolled during the same period and 27 received study treatment. In patients with IPF, PA101 reduced daytime cough frequency by 31·1% at day 14 compared with placebo; daytime cough frequency decreased from a mean 55 (SD 55) coughs per h at baseline to 39 (29) coughs per h at day 14 following treatment with PA101, versus 51 (37) coughs per h at baseline to 52 (40) cough per h following placebo treatment (ratio of least-squares [LS] means 0·67, 95% CI 0·48–0·94, p=0·0241). By contrast, no treatment benefit for PA101 was observed in the CIC cohort; mean reduction of daytime cough frequency at day 14 for PA101 adjusted for placebo was 6·2% (ratio of LS means 1·27, 0·78–2·06, p=0·31). PA101 was well tolerated in both cohorts. The incidence of adverse events was similar between PA101 and placebo treatments, most adverse events were mild in severity, and no severe adverse events or serious adverse events were reported. Interpretation This study suggests that the mechanism of cough in IPF might be disease specific. Inhaled PA101 could be a treatment option for chronic cough in patients with IPF and warrants further investigation